Morphiex’s antisense take on CD47 aims for more than eating
Morphiex enters the CD47 race with an antisense approach that activates immunity
Morphiex is breaking from the CD47 pack by undercutting the target’s expression on both tumor and immune cells instead of just blocking tumors’ “don’t eat me” signals via SIRPA. The company believes its antisense approach could unleash T cell and NK cell activity, and avoid the red blood cell toxicity that has loomed over the CD47 space.
“Everyone else is blocking it, but we’re actually reducing the expression of CD47,” said Anthony Schwartz, co-founder and CEO of Morphiex Biotherapeutics Inc.